It's Tuesday, June 25th.

Welcome to Market Fullry.

I'm Chris Hill joining me in studio.

Back in the United States of America, it's Jason Moser, looking tanned, rested and ready. I feel like in my defense I probably am

always looking tanned to some level. Like I was adopted so I don't know necessarily

the bloodline there but we've all determined that there must be some

Mediterranean and me yeah maybe but as someone who sees you pretty much every

day you're looking more too maybe a little bit more tan there was a lot of

sun there you're a little bit closer to the equator in

Costa Rica. Yeah we'll get to that and we'll get to some drama or maybe not

drama between Warren Buffett and 3G capital. We'll unpack that as well. Once again,

we're going to start with a big deal this time in the health care space, and I'm saying

health care just the huge umbrella of health care

Abbvie buying Alergan the maker of Botox this is a 63 billion dollar deal cash and stock.

Allegan, if you're a shareholder, well you're having a heck of a good day because the buyout price is 45% higher than yesterday's close. I am curious though at the fact that Allegan is now only

Trading up about 25, 28 percent higher.

We'll get to whether or not this deal goes through,

but this is yet another big deal.

Yeah, yeah, I mean, the, whether it goes through

is going to be interesting just from the perspective that it wasn't all that long ago that there was an offer made, I believe for Alargin for quite a bit more than today's offer.

But then also the recent calls have been for the company actually to split up and spin

off some of its assets to realize more value that way.

...